The aggregation of alpha‐synuclein is stimulated by FK506 binding proteins as shown by fluorescence correlation spectroscopy

Aggregation of ±‐synuclein (±‐SYN) plays a key role in Parkinson's disease (PD). We have used fluorescence correlation spectroscopy (FCS) to study ±‐SYN aggregation in vitro and discovered that this process is clearly accelerated by addition of FK506 binding proteins (FKBPs). This effect was observed both with E. coli SlyD FKBP and with human FKBP12 and was counteracted by FK506, a specific inhibitor of FKBP. The ±‐SYN aggregates formed in the presence of FKBP12 showed fibrillar morphology. The rotamase activity of FKBP apparently accelerates the folding and subsequent aggregation of ±‐SYN. Since FK506 and other non‐immunosuppressive FKBP inhibitors are known to display neuroregenerative and neuroprotective properties in disease models, the observed inhibition of rotamase activity and ±‐SYN aggregation, may explain their mode of action. Our results open perspectives for the treatment of PD with immunophilin ligands that inhibit a specific member of the FKBP family.

[1]  A. Tanaka.  [A receptor for the immunosuppressant FK506 is a cis-trans peptidyl-prolyl isomerase]. , 2007, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme.

[2]  J. Vercammen,et al.  Measuring protein‐protein interactions inside living cells using single color fluorescence correlation spectroscopy. Application to human immunodeficiency virus type 1 integrase and LEDGF/p75 , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[3]  V. Subramaniam,et al.  Impact of the acidic C-terminal region comprising amino acids 109-140 on alpha-synuclein aggregation in vitro. , 2004, Biochemistry.

[4]  J. Vercammen,et al.  Correct diffusion coefficients of proteins in fluorescence correlation spectroscopy. Application to tubulin oligomers induced by Mg2+ and Paclitaxel. , 2004, Biophysical journal.

[5]  A Dürr,et al.  Causal relation between α-synuclein locus duplication as a cause of familial Parkinson's disease , 2004, The Lancet.

[6]  Philippe Amouyel,et al.  α-synuclein locus duplication as a cause of familial Parkinson's disease , 2004, The Lancet.

[7]  J. Hoenicka,et al.  The new mutation, E46K, of α‐synuclein causes parkinson and Lewy body dementia , 2004, Annals of neurology.

[8]  S. Heiland,et al.  Changes in peptidyl-prolyl cis/trans isomerase activity and fk506 binding protein expression following neuroprotection by fk506 in the ischemic rat brain , 2003, Neuroscience.

[9]  C. Achim,et al.  Immunophilins in nervous system degeneration and regeneration. , 2003, Current topics in medicinal chemistry.

[10]  Andrzej Galat,et al.  Peptidylprolyl cis/trans isomerases (immunophilins): biological diversity--targets--functions. , 2003, Current topics in medicinal chemistry.

[11]  R. Blakely,et al.  Dopaminergic neuronal loss and motor deficits in Caenorhabditis elegans overexpressing human α‐synuclein , 2003, Journal of neurochemistry.

[12]  B. Strooper,et al.  Neuropathology and Neurodegeneration in Rodent Brain Induced by Lentiviral Vectormediated Overexpression of α‐Synuclein , 2003, Brain pathology.

[13]  P. Lansbury,et al.  Zeroing in on the pathogenic form of alpha-synuclein and its mechanism of neurotoxicity in Parkinson's disease. , 2003, Biochemistry.

[14]  V. Subramaniam,et al.  Cellular Polyamines Promote the Aggregation of α-Synuclein* , 2003, The Journal of Biological Chemistry.

[15]  C. Achim,et al.  Immunophilins and their ligands: insights into survival and growth of human neurons , 2002, Physiology & Behavior.

[16]  Jo Vercammen,et al.  DNA-induced Polymerization of HIV-1 Integrase Analyzed with Fluorescence Fluctuation Spectroscopy* , 2002, The Journal of Biological Chemistry.

[17]  P. Aebischer,et al.  α-Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[18]  V. Uversky,et al.  Heparin and other glycosaminoglycans stimulate the formation of amyloid fibrils from alpha-synuclein in vitro. , 2002, Biochemistry.

[19]  C. Achim,et al.  The immunosuppressant drug FK506 is a potent trophic agent for human fetal neurons. , 2001, Brain research. Developmental brain research.

[20]  L. Missiaen,et al.  The Conserved Sites for the FK506-binding Proteins in Ryanodine Receptors and Inositol 1,4,5-Trisphosphate Receptors Are Structurally and Functionally Different* , 2001, The Journal of Biological Chemistry.

[21]  V. Uversky,et al.  Trimethylamine‐N‐oxide‐induced folding of α‐synuclein , 2001 .

[22]  V. Uversky,et al.  Stabilization of Partially Folded Conformation during α-Synuclein Oligomerization in Both Purified and Cytosolic Preparations* , 2001, The Journal of Biological Chemistry.

[23]  V. Uversky,et al.  Effect of familial Parkinson's disease point mutations A30P and A53T on the structural properties, aggregation, and fibrillation of human alpha-synuclein. , 2001, Biochemistry.

[24]  T. Dawson,et al.  Neuroimmunophilin ligands exert neuroregeneration and neuroprotection in midbrain dopaminergic neurons , 2001, The European journal of neuroscience.

[25]  V. Uversky,et al.  Evidence for a Partially Folded Intermediate in α-Synuclein Fibril Formation* , 2001, The Journal of Biological Chemistry.

[26]  L. Missiaen,et al.  Characterization and mapping of the 12 kDa FK506-binding protein (FKBP12)-binding site on different isoforms of the ryanodine receptor and of the inositol 1,4,5-trisphosphate receptor. , 2001, The Biochemical journal.

[27]  Glenda M. Halliday,et al.  Clinical and pathological features of a parkinsonian syndrome in a family with an Ala53Thr α‐synuclein mutation , 2001 .

[28]  J Q Trojanowski,et al.  A Hydrophobic Stretch of 12 Amino Acid Residues in the Middle of α-Synuclein Is Essential for Filament Assembly* , 2001, The Journal of Biological Chemistry.

[29]  V. Uversky,et al.  Why are “natively unfolded” proteins unstructured under physiologic conditions? , 2000, Proteins.

[30]  R. Perrin,et al.  Interaction of human alpha-Synuclein and Parkinson's disease variants with phospholipids. Structural analysis using site-directed mutagenesis. , 2000, The Journal of biological chemistry.

[31]  Christian Haass,et al.  Subcellular Localization of Wild-Type and Parkinson's Disease-Associated Mutant α-Synuclein in Human and Transgenic Mouse Brain , 2000, The Journal of Neuroscience.

[32]  Watt W. Webb,et al.  Fluorescence correlation spectroscopy , 2000 .

[33]  W. Bender,et al.  A Drosophila model of Parkinson's disease , 2000, Nature.

[34]  M. Citron,et al.  alpha-synuclein fibrillogenesis is nucleation-dependent. Implications for the pathogenesis of Parkinson's disease. , 1999, The Journal of biological chemistry.

[35]  P. Davies,et al.  The prolyl isomerase Pin1 restores the function of Alzheimer-associated phosphorylated tau protein , 1999, Nature.

[36]  M. Matzuk,et al.  Immunophilin FK506-binding protein 52 (not FK506-binding protein 12) mediates the neurotrophic action of FK506. , 1999, The Journal of pharmacology and experimental therapeutics.

[37]  Peter T. Lansbury,et al.  Accelerated in vitro fibril formation by a mutant α-synuclein linked to early-onset Parkinson disease , 1998, Nature Medicine.

[38]  R. Crowther,et al.  α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with Lewy bodies , 1998 .

[39]  I. Baskakov,et al.  Forcing Thermodynamically Unfolded Proteins to Fold* , 1998, The Journal of Biological Chemistry.

[40]  R. S. Muir,et al.  Functions of FKBP12 and mitochondrial cyclophilin active site residues in vitro and in vivo in Saccharomyces cerevisiae. , 1997, Molecular biology of the cell.

[41]  P. Chaturvedi,et al.  A Nonimmunosuppressant FKBP-12 Ligand Increases Nerve Regeneration , 1997, Experimental Neurology.

[42]  Robert L. Nussbaum,et al.  Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease , 1997 .

[43]  G. Fischer,et al.  Comparative mutational analysis of peptidyl prolyl cis/trans isomerases: active sites of Escherichia coli trigger factor and human FKBP12 , 1997, FEBS letters.

[44]  J. H. Li,et al.  Neurotrophic immunophilin ligands stimulate structural and functional recovery in neurodegenerative animal models. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[45]  S. Fleischer,et al.  Affinity purification of the ryanodine receptor/calcium release channel from fast twitch skeletal muscle based on its tight association with FKBP12. , 1995, Biochemical and biophysical research communications.

[46]  P. Lansbury,et al.  The core Alzheimer's peptide NAC forms amyloid fibrils which seed and are seeded by beta-amyloid: is NAC a common trigger or target in neurodegenerative disease? , 1995, Chemistry & biology.

[47]  N. Sigal,et al.  FK‐506–A Novel Immunosuppressant , 1993, Annals of the New York Academy of Sciences.

[48]  D. Livingston,et al.  PPIase catalysis by human FK506-binding protein proceeds through a conformational twist mechanism. , 1992, The Journal of biological chemistry.

[49]  S. Schreiber,et al.  Inhibition of FKBP rotamase activity by immunosuppressant FK506: twisted amide surrogate. , 1990, Science.

[50]  S. Schreiber,et al.  A receptor for the immuno-suppressant FK506 is a cis–trans peptidyl-prolyl isomerase , 1989, Nature.

[51]  E. Ohama,et al.  Parkinson's disease: Distribution of Lewy bodies and monoamine neuron system , 1976, Acta Neuropathologica.

[52]  W. Webb,et al.  Fluorescence correlation spectroscopy. II. An experimental realization , 1974, Biopolymers.

[53]  A Dürr,et al.  Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease. , 2004, Lancet.

[54]  Philippe Amouyel,et al.  Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. , 2004, Lancet.

[55]  V. Subramaniam,et al.  Cellular polyamines promote the aggregation of alpha-synuclein. , 2003, The Journal of biological chemistry.

[56]  J. Ridet,et al.  alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease. , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[57]  V. Uversky,et al.  Trimethylamine-N-oxide-induced folding of alpha-synuclein. , 2001, FEBS letters.

[58]  R. Krüger,et al.  Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. , 1998, Nature genetics.

[59]  M G Spillantini,et al.  Alpha-synuclein in Lewy bodies. , 1997, Nature.

[60]  S E Ide,et al.  Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. , 1997, Science.

[61]  D. Magde.  Concentration correlation analysis and chemical kinetics. , 1977, Molecular biology, biochemistry, and biophysics.